The demarcation between drugs and medical devices

Latest Perspectives

• May 03

  2022

  Amgen Inc. v. Sanofi: Does the Supreme Court’s Call for the Solicitor General’s Views Signal an Intention to Resolve Important Enablement Questions for Genus Claims?

  Immuno-Innovation Blog
• April 20

  2022

  Does PTAB’s Ex Parte Cellect Decision Endanger Biopharmaceutical Patent Terms?

• April 18

  2022

  Does the PTAB’s Recent Ex Parte Cellect Decision Signal Concern for the Valuable Patent Terms of Biopharmaceuticals?

  Immuno-Innovation Blog